These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 2413459)

  • 1. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
    Mitsuya H; Weinhold KJ; Furman PA; St Clair MH; Lehrman SN; Gallo RC; Bolognesi D; Barry DW; Broder S
    Proc Natl Acad Sci U S A; 1985 Oct; 82(20):7096-100. PubMed ID: 2413459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
    Mitsuya H; Broder S
    Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1911-5. PubMed ID: 3006077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro.
    Nakashima H; Matsui T; Harada S; Kobayashi N; Matsuda A; Ueda T; Yamamoto N
    Antimicrob Agents Chemother; 1986 Dec; 30(6):933-7. PubMed ID: 2434024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T-cell lymphotropic virus (HTLV-III)/lymphadenopathy-associated virus (LAV).
    Balzarini J; Mitsuya H; De Clercq E; Broder S
    Int J Cancer; 1986 Mar; 37(3):451-7. PubMed ID: 2419266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1.
    Sarin PS; Sun DK; Thornton AH; Naylor PH; Goldstein AL
    Science; 1986 May; 232(4754):1135-7. PubMed ID: 3010464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of the discovery of HTLV-III for the treatment of AIDS.
    Yarchoan R; Mitsuya H; Matsushita S; Broder S
    Cancer Res; 1985 Sep; 45(9 Suppl):4685s-4688s. PubMed ID: 2410113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine.
    Smith MS; Brian EL; Pagano JS
    J Virol; 1987 Dec; 61(12):3769-73. PubMed ID: 2446006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.
    Sodroski J; Goh WC; Rosen C; Tartar A; Portetelle D; Burny A; Haseltine W
    Science; 1986 Mar; 231(4745):1549-53. PubMed ID: 3006244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular clone of HTLV-III with biological activity.
    Fisher AG; Collalti E; Ratner L; Gallo RC; Wong-Staal F
    Nature; 1985 Jul 18-24; 316(6025):262-5. PubMed ID: 2410792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.
    Yarchoan R; Klecker RW; Weinhold KJ; Markham PD; Lyerly HK; Durack DT; Gelmann E; Lehrman SN; Blum RM; Barry DW
    Lancet; 1986 Mar; 1(8481):575-80. PubMed ID: 2869302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.
    Mitsuya H; Matsushita S; Yarchoan R; Broder S
    Princess Takamatsu Symp; 1984; 15():277-88. PubMed ID: 6085846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
    Sandstrom EG; Kaplan JC; Byington RE; Hirsch MS
    Lancet; 1985 Jun; 1(8444):1480-2. PubMed ID: 2409414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients.
    Arya SK; Gallo RC
    Proc Natl Acad Sci U S A; 1986 Apr; 83(7):2209-13. PubMed ID: 3008154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.
    Sodroski J; Goh WC; Rosen C; Campbell K; Haseltine WA
    Nature; 1986 Jul 31-Aug 6; 322(6078):470-4. PubMed ID: 3016552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous production of a cytopathic human T-lymphotropic virus in a permissive neoplastic T-cell line.
    Getchell JP; Heath JL; Hicks DR; Sporborg C; McGrath CR; Kalyanaraman VS
    J Clin Microbiol; 1986 Apr; 23(4):737-42. PubMed ID: 2422205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine.
    Ruprecht RM; O'Brien LG; Rossoni LD; Nusinoff-Lehrman S
    Nature; 1986 Oct 2-8; 323(6087):467-9. PubMed ID: 3463867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pathogenic retrovirus (HTLV-III) linked to AIDS.
    Broder S; Gallo RC
    N Engl J Med; 1984 Nov; 311(20):1292-7. PubMed ID: 6208484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of retroviral DNA polymerase: their implication in the treatment of AIDS.
    Chandra P; Vogel A; Gerber T
    Cancer Res; 1985 Sep; 45(9 Suppl):4677s-4684s. PubMed ID: 2410112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of human T-lymphotropic leukemia virus type III associated with the acquired immunodeficiency syndrome.
    Wong-Staal F; Hahn BH; Shaw GM; Arya SK; Harper M; Gonda M; Gilden R; Ratner L; Starcich B; Okamoto T
    Princess Takamatsu Symp; 1984; 15():291-300. PubMed ID: 6100646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I.
    Matsushita S; Mitsuya H; Reitz MS; Broder S
    J Clin Invest; 1987 Aug; 80(2):394-400. PubMed ID: 3038956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.